Stroke-related disability or death within 30 days is rare after discharge from the emergency department following a visit for ...
Despite living with canine cognitive dysfunction syndrome (similar to dementia in humans), the 16-year-old dog suddenly made a "U-turn"—remembering he needed his nighttime snack, as the text overlay ...
Vanda Pharmaceuticals received FDA approval for Nereus for motion sickness, and its shares offer upside potential into 2026 ...
The condition known as SSNHL, affects one ear at a time. Its onset can occur either during a single night, or it may develop ...
US FDA approves Vanda Pharma’s Nereus, an oral NK-1 receptor antagonist for prevention of vomiting induced by motion: Washington Friday, January 2, 2026, 15:00 Hrs [IST] Vanda P ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...
The FDA has approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for preventing motion-induced vomiting in adults ...
More than 90 million Americans will experience a balance disorder in their lifetime, and balance-related falls account for more than half of all accidental deaths among older adults. Many of ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback